HebeCell Entered into a Collaboration with Logomix to Research and Develop Next Gen Genomically Engineered PSC-NK Cells
Shots:
- The companies collaborated to research and develop gene-edited NK cells and discover genetic modifications for next-generation designer NK cells
- The collaboration will combine a PSC-based platform with genome editing capabilities to advance the new development for screening de novo genetic modifications enhancing the persistence & efficacy of protoNK cells against cancers
- Logomix develops multiple iPS cell lines as universal donor cells available for licensing by using its genome engineering platform Geno-Writing. This technology enables Mb-scale & scarless alterations that may be applied to any sequences at either or both alleles making it the perfect tool for creating sources of allogeneic cells therapy with desired gene edits
Ref: Businesswire | Image: Hebecell
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
